RTI Surgical® Applauds Blue Cross and Blue Shield of Alabama’s Positive Coverage Decision for Minimally Invasive Sacroilia...
April 04 2019 - 7:30AM
Decision may help more patients access RTI’s
SImmetry® Sacroiliac Joint Fusion System, a minimally invasive
surgical solution for sacroiliac (SI) joint dysfunction
RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical
implant company, applauds Blue Cross and Blue Shield of Alabama
(BCBSAL), the largest provider of healthcare benefits in Alabama,
for issuing a positive coverage decision for minimally invasive
sacroiliac (SI) joint fusion surgery, effective March 18, 2019.
This decision expands access to RTI’s SImmetry Sacroiliac Joint
Fusion System for appropriate BCBSAL members considering treatment
for SI joint pain or dysfunction. The SImmetry System is a
minimally invasive surgical solution that uses proprietary
decortication technology, bone graft and threaded fixation to
facilitate bone fusion, providing an opportunity for long-term pain
relief.
“RTI is encouraged by Blue Cross and Blue Shield of Alabama’s
recent decision to expand treatment options for patients with SI
joint pain or dysfunction,” said Camille Farhat, President and CEO,
RTI Surgical. “The effectiveness of the SImmetry System is
supported by a growing body of evidence suggesting long-term pain
reduction and improved quality of life for patients. We look
forward to sharing more data from the ongoing EVoluSIon Clinical
Study in 2019.”
It has been reported that up to 30 percent of all chronic low
back pain, the second most common cause of disability in American
adults, is due to SI joint dysfunction. SI joint fusion surgery
using the SImmetry System is designed to stabilize the
dysfunctional SI joint by fusing the sacrum and the pelvic bone
together.
Enrollment for the EVoluSIon Clinical Study evaluating the
impact of the SImmetry System on SI joint fusion and pain reduction
in 250 patients has been completed across 23 sites. An early
analysis of the first 50 patients published in December 2017 showed
over 50% pain reduction reported by patients at 6 months
post-procedure, as well as 50% fewer patients who were on opioids
at 6 months post-procedure.i A separate study on the SImmetry
System demonstrated a 73 percent reduction in average pain over 24
months.ii Clinical outcomes from 100 patients presented at the
International Society for the Advancement of Spine Surgery (ISASS)
2018 Annual Meeting showed the SImmetry System provided a 56
percent reduction in average patient-reported pain, and a
statistically significant reduction in the use of opioids and other
pain medications at six months.iii
For more information, please view the BCBS Alabama final
Sacroiliac Joint Fusion policy.
About RTI Surgical Holdings, Inc.
RTI Surgical is a leading global surgical implant company
providing surgeons with safe biologic, metal and synthetic
implants. Committed to delivering a higher standard, RTI’s implants
are used in sports medicine, general surgery, spine, orthopedic and
trauma procedures and are distributed in nearly 50 countries. RTI
has four manufacturing facilities throughout the U.S. and Europe.
RTI is accredited in the U.S. by the American Association of Tissue
Banks and is a member of AdvaMed. For more information, please
visit www.rtix.com. Connect with us
on LinkedIn and Twitter.
Forward-Looking Statements
This communication contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are based on management’s
current expectations, estimates and projections about our industry,
our management's beliefs and certain assumptions made by our
management. Words such as "anticipates," "expects," "intends,"
"plans," "believes," "seeks," "estimates," variations of such words
and similar expressions are intended to identify such
forward-looking statements. In addition, except for historical
information, any statements made in this communication about
anticipated financial results, growth rates, new product
introductions, future operational improvements, gaining market
share and results or regulatory actions or approvals or changes to
agreements with distributors also are forward-looking statements.
These statements are not guarantees of future performance and are
subject to risks and uncertainties, including the risks described
in public filings with the U.S. Securities and Exchange Commission
(SEC). Our actual results may differ materially from the
anticipated results reflected in these forward-looking statements.
Copies of the company's SEC filings may be obtained by contacting
the company or the SEC or by visiting RTI's website
at www.rtix.com or the SEC's website
at www.sec.gov.
References
i Araghi, A, et al, Pain and Opioid use Outcomes following
Minimally Invasive Sacroiliac Joint Fusion with Decortication and
Bone Grafting: The EVoluSIon Clinical Trial. The Open
Orthopaedics Journal, 2017, 11, 1440-1448.
ii Cross, WW et al, Minimally Invasive Sacroiliac Joint Fusion:
2-year Radiographic and Clinical Outcomes with a Principles-Based
SIJ Fusion System. The Open Orthopaedics Journal, 2018, 12,
7-16.
iii Araghi, et al. Minimally Invasive Sacroiliac Joint Fusion
Surgery with Decortication and Threaded Implants: Analysis of
EVoluSIon Study. Presented at ISASS 2018.
Steven Cohen Media Contact scohen@rtix.com +1
847 648 0861
Molly Poarch Investor Contact mpoarch@rtix.com
+1 224 287 2661
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Sep 2023 to Sep 2024